Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies
Treatment with recombinant therapy RUCONEST® and plasma-derived C1 treatments requires significantly less re-dosing than icatibant (Firazyr®) to resolve HAE attacks Leiden, The Netherlands, 7 December 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks